Vir Biotechnology

– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep…

<!-- Name:DistributionId Value:8841557 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8754497 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8748385 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical…

– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research…

– First award from the agency’s solicitation for contracts for Pre-Exposure Prophylaxis for Influenza – – Initial investment of approximately $55 million from Biomedical Advanced Research…

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have…

– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 – – Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm…

SAN FRANCISCO, March 25, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration…